10:32 AM EDT, 10/24/2024 (MT Newswires) -- Zai Lab ( ZLAB ) said Thursday that results from the ongoing phase 1a/1b trial of ZL-1310 in people with extensive-stage small cell lung cancer following at least one previous platinum-based chemotherapy treatment showed "promising" objective response rates and safety profile.

The objective response rate was 74% in all tested dose levels of ZL-1310 in people with the disease, the company said.

The firm showcased the data at the conference in Barcelona regarding the current phase 1a part of the research, which involves increasing the dosage of the drug in four different groups, including outcomes from a total of 25 participants.

"ZL-1310 anti-tumor activity was demonstrated across all dose levels," Zai Lab ( ZLAB ) said.

Also, ZL-1310 was "well tolerated across all dose levels with the majority of treatment-emergent adverse events (TEAE) being Grade 1 or 2," the company said.

The shares of Zai Lab ( ZLAB ) were rising past 15% in recent trading.

Price: 33.41, Change: +4.47, Percent Change: +15.45